240 per cent growth in net profit: This small-cap stock announced robust results!

The company has an impressive client list which includes Intas, Mankind and Indoco Remedies, among others.

Kilitch Drugs (India) is a successful pharmaceutical solutions company with a major focus on the African region, the company has gained a strong foothold across key African countries, offering a wide range of 350 products. Kilitch Drug operates a manufacturing plant in Mumbai, which is certified by reputable authorities such as WHO, WHO GMP, ISO 9001. Notably, the company has also started a greenfield project in Ethiopia for Cephalosporins injectables. The company has an impressive client list which includes Intas, Mankind and Indoco Remedies, among others. 

Kilitch Drugs has reported its Q4FY23 financial results, revealing a remarkable surge in sales by 35.12 per cent to reach Rs 43.28 crore. The company's EBITDA witnessed a substantial growth of 71.31 per cent to Rs 8.21 crore and their net profit experienced a notable jump of 69.87 per cent to Rs 5.13 crore. The company achieved a sales growth of 38 per cent (CAGR) over the span of three years, while its profit witnessed a remarkable growth of 246 per cent (CAGR) during the past 3 years. 

DSIJ offers a product 'Tiny Treasure' with recommendations for Small-Cap & micro-cap stocks based on research and analysis to help subscribers make informed investment decisions. If this interests you, then do download the product details pdf here

On Wednesday, shares of Kilitch Drugs plunged by 5 per cent to close at Rs 201.25. 

Over the past 3 years the company has delivered exceptional returns of 95.11 per cent, while over the past 5 years, it has provided significant returns of 140.27 per cent. 

Investors should keep a close eye on this trending stock.